Search

Displaying results 7551 - 7560 of 10000 in total
  1. Drug

    MCC

    go.drugbank.com/drugs/DB05282
    Investigational

    The product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing facility in Pointe-Claire, Quebec. … Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria.

  2. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  3. Drug

    ARG201

    go.drugbank.com/drugs/DB06621
    Experimental

    This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma) … ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc).

  4. Drug

    Thymoquinone

    go.drugbank.com/drugs/DB16447
    Investigational

    Thymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.

  5. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. … It was under investigation in clinical trials to treat Inflammatory Arthritis. In 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA.

  6. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    It is being developed by Vitae Pharmaceuticals. … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.

  7. Drug

    Recombinant Super-Compound Interferon

    go.drugbank.com/drugs/DB15752
    Investigational

    Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.

  8. Drug

    IRX-5183

    go.drugbank.com/drugs/DB05653
    Investigational

  9. Drug

    Imisopasem manganese

    go.drugbank.com/drugs/DB04976
    Investigational

    M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.

  10. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.